Drug Type AAV based gene therapy |
Synonyms |
Target |
Action- |
Mechanism NAGLU replacements(Alpha-N-acetylglucosaminidase replacements), Gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucopolysaccharidosis III | Preclinical | France | 17 Sep 2013 | |
Lower Urinary Tract Symptoms | Preclinical | Italy | 01 Sep 2013 | |
Lower Urinary Tract Symptoms | Preclinical | Poland | 01 Sep 2013 | |
Lower Urinary Tract Symptoms | Preclinical | Spain | 01 Sep 2013 | |
Lower Urinary Tract Symptoms | Preclinical | United Kingdom | 01 Sep 2013 | |
Lower Urinary Tract Symptoms | Preclinical | Germany | 01 Sep 2013 |